Clover Health Investments, Corp. (CLOV) Stock Analysis

Clover Health is a technology-led Medicare Advantage insurer combining PPO and HMO plans with the Clover Assistant clinical platform and its external licensing subsidiary, Counterpart Health. Its value proposition is affordable, wide-network coverage, including $0 monthly premiums and low out-of-pocket maximums, while physicians receive real-time data and coding support for proactive chronic-care management. **The financial inflection is now visible:** Q2 2026 revenue rose 55.6% year over year to $743.2 million, GAAP net income reached $28.0 million versus a $10.6 million loss, adjusted EBITDA increased 139.2% to $40.9 million, and MA membership rose 48.7% to 156,840. Management raised FY2026 revenue guidance to $2.92-$3.00 billion and GAAP net income guidance to $20-$35 million. The recalculated 4.5 Star rating could deliver approximately $120 million of 2027 quality bonus payments, although CMS has appealed. Counterpart provides longer-term SaaS upside, but its revenue remains not yet significant. At $4.30, the report views the stock as undervalued, with a probability-weighted five-year target of approximately $7.21-$7.22 and major upside if software scales.